This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since 2018, biotech company Mikrobiomik has been researching, development and producing innovative biological medicines based on the human microbiome. The specific representation of these events differed between the treatments, highlighting potential differences in sideeffect profiles that should be explored in further studies.
On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. cases per 100,000 people in 2018. “In In the UK, the mean annual incidence of Lyme disease grew from 0.38
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases. rises/second (SD 0.0628) in the placebo group.
A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of sideeffects. The same can be said for the US. of adults were overweight, 42.4%
The 2021 PURE report indicated that two out of three patients are concerned about potential sideeffects before taking their first dose, and again, this is more evident in women than men. Hospital Admissions Associated with Medication Non-Adherence: A Systematic Review of Prospective Observational Studies.” May 23, 2018.
A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of sideeffects. The same can be said for the US. of adults were overweight, 42.4%
The document would include the drug/biological product name, sideeffects, directions for use, safety information, and a concise summary of indications and uses. According to a 2018 study , nonadherence is especially an issue in the case of chronic illness where patients may be expected to take medications at least once daily.
Fox says adjuvant protein subunit vaccines can be a safer approach compared to live attenuated virus vaccines as there is a minimized risk of developing sideeffects. Results from the Phase II trial were released for the vaccine in September 2018.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content